Philippe Mathurin

Philippe Mathurin

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Philippe Mathurin

Université Lille, CHU de Lille, Service des maladies de l'appareil digestif, Hôpital Huriez, INFINITE-U1286, Lille, France

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2016 in Gastroenterology
Verified
Journal Article
Open access
PDF file
VRVlad Ratziu
Vlad Ratziu
SHStephen A. Harrison
Stephen A. Harrison
SFSven M Francque
Sven M Francque
PBPierre Bedossa
Pierre Bedossa
PLPhilippe Lehert
Philippe Lehert
JGJ. Gallegos-Orozco
J. Gallegos-Orozco
Background & Aims Elafibranor is an agonist of the peroxisome proliferator−activated receptor-α and peroxisome proliferator−activated receptor-δ. Elafibranor improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation. We assessed the safety and efficacy of elafibranor in an international, randomized, double-blind placebo-controlled trial of patients with nonalcoholic steatohepatitis (NASH). Methods Patients with NASH without cirrhosis were randomly assigned to groups given elafibranor 80 mg (n = 93), elafibranor 120 mg (n = 91), or placebo (n = 92) each day for 52 weeks at sites in Europe and the United States. Clinical and laboratory evaluations were performed every 2 months during this 1-year period. Liver biopsies were then collected and patients were assessed 3 months later. The primary outcome was resolution of NASH without fibrosis worsening, using protocol-defined and modified definitions. Data from the groups given the different doses of elafibranor were compared with those from the placebo group using step-down logistic regression, adjusting for baseline nonalcoholic fatty liver disease activity score. Results In intention-to-treat analysis, there was no significant difference between the elafibranor and placebo groups in the protocol-defined primary outcome. However, NASH resolved without fibrosis worsening in a higher proportion of patients in the 120-mg elafibranor group vs the placebo group (19% vs 12%; odds ratio = 2.31; 95% confidence interval: 1.02−5.24; P = .045), based on a post-hoc analysis for the modified definition. In post-hoc analyses of patients with nonalcoholic fatty liver disease activity score ≥4 (n = 234), elafibranor 120 mg resolved NASH in larger proportions of patients than placebo based on the protocol definition (20% vs 11%; odds ratio = 3.16; 95% confidence interval: 1.22−8.13; P = .018) and the modified definitions (19% vs 9%; odds ratio = 3.52; 95% confidence interval: 1.32–9.40; P = .013). Patients with NASH resolution after receiving elafibranor 120 mg had reduced liver fibrosis stages compared with those without NASH resolution (mean reduction of 0.65 ± 0.61 in responders for the primary outcome vs an increase of 0.10 ± 0.98 in nonresponders; P < .001). Liver enzymes, lipids, glucose profiles, and markers of systemic inflammation were significantly reduced in the elafibranor 120-mg group vs the placebo group. Elafibranor was well tolerated and did not cause weight gain or cardiac events, but did produce a mild, reversible increase in serum creatinine (effect size vs placebo: increase of 4.31 ± 1.19 μmol/L; P < .001). Conclusions A post-hoc analysis of data from trial of patients with NASH showed that elafibranor (120 mg/d for 1 year) resolved NASH without fibrosis worsening, based on a modified definition, in the intention-to-treat analysis and in patients with moderate or severe NASH. However, the predefined end point was not met in the intention to treat population. Elafibranor was well tolerated and improved patients’ cardiometabolic risk profile. ClinicalTrials.gov number: NCT01694849.

10 November 2011 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
PMPhilippe Mathurin
Philippe Mathurin
CMChristophe Moreno
Christophe Moreno
DSDidier Samuel
Didier Samuel
JDJérôme Dumortier
Jérôme Dumortier
JSJulia Salleron
Julia Salleron
JDJean-Charles Duclos-Vallée
Jean-Charles Duclos-Vallée
A 6-month abstinence from alcohol is usually required before patients with severe alcoholic hepatitis are considered for liver transplantation. Patients whose hepatitis is not responding to medical therapy have a 6-month survival rate of approximately 30%. Since most alcoholic hepatitis deaths occur within 2 months, early liver transplantation is attractive but controversial. We selected patients from seven centers for early liver transplantation. The patients had no prior episodes of alcoholic hepatitis and had scores of 0.45 or higher according to the Lille model (which calculates scores ranging from 0 to 1, with a score ≥0.45 indicating nonresponse to medical therapy and an increased risk of death in the absence of transplantation) or rapid worsening of liver function despite medical therapy. Selected patients also had supportive family members, no severe coexisting conditions, and a commitment to alcohol abstinence. Survival was compared between patients who underwent early liver transplantation and matched patients who did not. In all, 26 patients with severe alcoholic hepatitis at high risk of death (median Lille score, 0.88) were selected and placed on the list for a liver transplant within a median of 13 days after nonresponse to medical therapy. Fewer than 2% of patients admitted for an episode of severe alcoholic hepatitis were selected. The centers used 2.9% of available grafts for this indication. The cumulative 6-month survival rate (±SE) was higher among patients who received early transplantation than among those who did not (77±8% vs. 23±8%, P<0.001). This benefit of early transplantation was maintained through 2 years of follow-up (hazard ratio, 6.08; P=0.004). Three patients resumed drinking alcohol: one at 720 days, one at 740 days, and one at 1140 days after transplantation. Early liver transplantation can improve survival in patients with a first episode of severe alcoholic hepatitis not responding to medical therapy. (Funded by Société Nationale Française de Gastroentérologie.)

17 March 2015 in Nature Reviews Gastroenterology & Hepatology
Verified
Journal Article
Closed access
ALAlexandre Louvet
Alexandre Louvet
PMPhilippe Mathurin
Philippe Mathurin

25 June 2009 in New England Journal of Medicine
Verified
Journal Article
Closed access
MLMichael R. Lucey
Michael R. Lucey
PMPhilippe Mathurin
Philippe Mathurin
TMTimothy R. Morgan
Timothy R. Morgan
The association between alcohol intake and alcoholic liver disease has been well documented, although cirrhosis of the liver develops in only a small proportion of heavy drinkers. This review focuses on alcoholic hepatitis, a treatable form of alcoholic liver disease. Since up to 40% of patients with severe alcoholic hepatitis die within 6 months after the onset of the clinical syndrome, appropriate diagnosis and treatment are essential.

1 August 2015 in Gastroenterology
Verified
Journal Article
Closed access
GLGuillaume Lassailly
Guillaume Lassailly
RCRobert Caiazzo
Robert Caiazzo
DBDavid Buob
David Buob
MPMarie Pigeyre
Marie Pigeyre
HVHélène Verkindt
Hélène Verkindt
PMPhilippe Mathurin
Philippe Mathurin

1 June 2007 in Hepatology
Verified
Journal Article
Closed access
PDF file
ALAlexandre Louvet
Alexandre Louvet
SNSylvie Naveau
Sylvie Naveau
MAMarcelle Abdelnour
Marcelle Abdelnour
MRMarie-José Ramond
Marie-José Ramond
EDEmmanuel Diaz
Emmanuel Diaz
PMPhilippe Mathurin
Philippe Mathurin